Gilead's HCV drug Sovaldi off to strong start, company mum on outlook
This article was originally published in Scrip
Executive Summary
Gilead Sciences reported better than expected quarterly sales plus strong early demand for its new hepatitis C drug Sovaldi. Company execs, however, refused to give a sales forecast for the new therapy, which is expected to be a multibillion-dollar product in its first full year on the market.